WhiteOak Capital Pharma and Heathcare Fund
Direct · GrowthAI Summary
WhiteOak Capital Pharma and Healthcare Fund has delivered a 1Y SIP XIRR of 14.46%, modestly ahead of the category average of 14.1%. On a lump-sum basis, the fund's 1Y CAGR of 21.86% dramatically outperformed the NIFTY 50's -2.9%, generating strong alpha of 20.88%. Over longer horizons, the fund's CAGR of 20.54% (3Y) and 11.86% (5Y) also comfortably exceeds the benchmark, though no long-horizon SIP XIRR data is available for direct category comparison.
The fund exhibits low volatility relative to the market with a beta of 0.59-0.63, and its downside capture of 44-51% versus upside capture of 73-78% indicates it has historically lost less than the index in down markets while still participating in a majority of gains. Risk-adjusted performance is solid, with a 1Y Calmar ratio of 1.143 and only one drawdown event exceeding 10%. The maximum drawdown was shallow at roughly -0.15% with a 57-day duration and 136-day recovery, suggesting contained recent downside.
As a sectoral/thematic fund, the portfolio is concentrated in the pharma and healthcare sector, which limits diversification by design. No individual holdings data was provided, so stock-level concentration cannot be assessed. Investors should assume the fund's fortunes are closely tied to the healthcare sector cycle rather than broad market trends.
The fund's 1Y SIP XIRR of 14.46% edges out the category average of 14.1%, placing it slightly above peers in the sectoral/thematic space. Calendar year returns show uneven consistency, with a strong 38.41% in 2024 and 23.72% in 2026 but a flat 1.37% in 2025, typical of sector funds. Its consistent positive alpha across 1Y to 15Y windows versus the NIFTY 50 suggests durable relative performance, though sector funds should be judged against sector benchmarks as well.
This fund is suitable for investors with high risk tolerance who want targeted exposure to the pharma and healthcare theme and already hold diversified core equity holdings. A horizon of at least 5-7 years is advisable to ride out sector cycles, as evidenced by the flat 2025 return. It should be treated as a satellite allocation rather than a core holding, ideally capped at a small share of the overall portfolio.
- Strong alpha generation versus the NIFTY 50, including 20.88% over 1Y and 15.85% over 3Y
- Favorable capture profile with downside capture of 44-51% against upside capture of 73-78%, indicating defensive characteristics
- Low beta of 0.59-0.63 and a 1Y Calmar ratio of 1.143, reflecting solid risk-adjusted returns
- Sectoral concentration in pharma and healthcare exposes investors to sharp sector-specific downturns, as seen in the flat 1.37% return in 2025
- The 1Y SIP XIRR of 14.46% only marginally exceeds the category average of 14.1%, and no long-horizon XIRR data is available to confirm sustained SIP outperformance
Generated on 09-09-2026, 3:37 AM. Verify before investing.
Gives more importance to longer time periods (10Y, 20Y) than shorter ones (1Y, 3Y). This balances out recent outperformance and gives a more realistic picture of what long-term returns might look like.
The largest peak-to-trough decline in the fund's NAV. Shows the worst-case loss an investor would have experienced at any point in the fund's history.
If you invested ₹1,00,000 every month via SIP, here's how this fund has historically performed across different time horizons.
| Duration | Invested | Median Value | XIRR | Min XIRR | Max XIRR |
|---|---|---|---|---|---|
| 1 Year | ₹12.00 L | ₹12.82 L | 16.5% | -4.7% | 54.9% |
SIP returns vs benchmark & category
Annualised SIP return (XIRR) over each rolling horizon — like-for-like, not lump-sum.
| Duration | Fund SIP XIRR | NIFTY 50 | Category avg | Fund edge |
|---|---|---|---|---|
| 1 Year | 16.5% | 14.4% | 14.1% | +2.0% |
| Duration | Mean | Median | Min | Max | Sharpe | Sortino | % Positive | Cat. Mean | Cat. Median |
|---|---|---|---|---|---|---|---|---|---|
| 1 Year | 17.6% | 17.7% | 0.6% | 35.5% | 1.25 | 10.72 | 100% | — | — |
Calmar Ratio by Duration
Compared against NIFTY 50
| Duration | Alpha | Beta | Upside Capture | Downside Capture | Fund CAGR | Bench CAGR |
|---|---|---|---|---|---|---|
| 1 Year | +20.88 | 0.59 | 72.7% | 44.3% | 21.9% | -2.9% |
| 3 Years | +15.85 | 0.63 | 77.5% | 50.8% | 20.5% | 3.6% |
| 5 Years | +8.08 | 0.63 | 77.5% | 50.8% | 11.9% | 2.1% |
| 7 Years | +4.95 | 0.63 | 77.5% | 50.8% | 8.3% | 1.5% |
| 10 Years | +2.66 | 0.63 | 77.5% | 50.8% | 5.8% | 1.1% |
| 12 Years | +1.79 | 0.63 | 77.5% | 50.8% | 4.8% | 0.9% |
| 15 Years | +0.93 | 0.63 | 77.5% | 50.8% | 3.8% | 0.7% |